BriaCell Therapeutics Corp.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT) is a clinical-stage immuno-oncology biotechnology company that develops novel targeted cellular immunotherapies designed to activate the patient's immune system against cancer cells across multiple indications. The company offers a portfolio of off-the-shelf and personalized whole-cell immunotherapies, including its lead candidate Bria-IMT (SV-BR-1-GM), a patented cell-based product expressing GM-CSF that received FDA Fast Track designation and is advancing in a pivotal Phase 3 trial in combination with immune checkpoint inhibitors for advanced metastatic breast cancer patients, including those with central nervous system metastases or resistant to prior antibody-drug conjugates; next-generation Bria-OTS and Bria-OTS+ platforms, which express multiple HLA types to enable HLA-matched off-the-shelf personalized treatments covering over 99% of patients via simple saliva testing and are enrolling in Phase 1/2 bucket trials for breast, prostate, lung cancer and melanoma, with enhanced Bria-OTS+ variants such as Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer completing GMP manufacturing for planned entry into clinic in first-half 2025; and supporting assets through subsidiary BriaPro Therapeutics Corp., including TILsRx platform targeting tumor-infiltrating lymphocytes and isoform-selective kinase inhibitors. BriaCell Therapeutics operates primarily in North America with clinical sites across 23 US states and collaborations involving leading institutions. Founded in 2006 and headquartered in West Vancouver, British Columbia, Canada, the company targets high-unmet-need solid tumors including metastatic breast cancer (over 40,000 US deaths annually) and prostate cancer. Recent developments include a October 2025 collaboration with Memorial Sloan Kettering Cancer Center's Therapeutics Accelerator to accelerate manufacturing, IND preparation and Phase 1 clinical development of Bria-OTS+ including Bria-BRES+; a November 2025 partnership between BriaPro and Receptor.AI to design AI-optimized anti-cancer isoform-selective kinase inhibitors; over $2 million National Cancer Institute SBIR grant to support Bria-PROS+ manufacturing and Phase 1/2a trial in metastatic prostate cancer; a July 2025 $15 million public offering to fund clinical programs; fourth positive Data Safety Monitoring Board recommendation with no safety concerns for the ongoing Phase 3 Bria-IMT trial; and preclinical data presented at SITC 2025 demonstrating potent anti-cancer activity for Bria-OTS+ candidates alongside Phase 2 survival and Phase 3 biomarker updates scheduled for SABCS 2025.
Company News
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™
BriaCell Therapeutics Announces Closing of Offering
BriaCell Presents Positive Clinical Data at ASCO 2026
BriaCell Therapeutics Announces Pricing of Offering
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
BriaCell Announces Six Clinical Data Presentations at ASCO 2026
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting